Navigation Links
Anadys Pharmaceuticals to Present at the Lazard Healthcare Conference
Date:11/10/2010

SAN DIEGO, Nov. 10, 2010 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that it will present at the Lazard 7th Annual Healthcare Conference on Wednesday, November 17, 2010 at 11:30 a.m. EST (8:30 a.m. PST).  The conference is being held at the St. Regis New York.  Steve Worland, Ph.D., President and Chief Executive Officer of Anadys, will provide an overview of Anadys and its clinical development programs.

The presentation will be webcast at the time of presentation and can be accessed on the Investor Relations page of the Company's website at www.anadyspharma.com.  Listeners are encouraged to visit the website approximately five minutes prior to each presentation to download or install any necessary software.  A replay of the presentation  will be available approximately one hour after the live webcast concludes and will be available through December 1, 2010.  

About Anadys

Anadys Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to improving patient care by developing novel medicines for the treatment of hepatitis C.  The Company believes hepatitis C represents a large unmet medical need in which meaningful improvements in treatment outcomes may be attainable with the introduction of new medicines.  Anadys is preparing to initiate a Phase IIb study of ANA598, the Company's direct-acting antiviral or DAA, added to current standard of care for the treatment of hepatitis C.  The Company is also preparing to resume clinical development of ANA773, the Company's oral, small-molecule inducer of endogenous interferons that acts via the Toll like receptor 7, or TLR7, pathway in hepatitis C.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forw
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Anadys Pharmaceuticals to Report Fourth Quarter and Year End 2009 Financial Results
2. Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients
3. Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights
4. Anadys Pharmaceuticals to Report Second Quarter 2009 Financial Results
5. Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598
6. Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights
7. Anadys Pharmaceuticals to Report First Quarter 2009 Financial Results
8. Anadys Pharmaceuticals to Present at Future Leaders in the Biotech Industry
9. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
10. Anadys Pharmaceuticals to Present at the Needham Focus on Infectious Disease Conference
11. Anadys Pharmaceuticals to Present at Rodman & Renshaw Annual Global Investment Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... HIGHLIGHTS:Q2 2015 Results (all changes ... Reported sales were $697 million compared to $701 million ... by 8%, and changes in foreign currency exchange rates ... 1%. , By business unit, organic sales growth ... in SAFC Commercial. , Reported diluted EPS was ...
(Date:7/29/2015)... July 30, 2015 Sanofi, ... for the second quarter of 2015. CEO ... and its performance in different businesses. ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Topics covered in ... - Performance drivers - ...
(Date:7/29/2015)... 2015: +14% CER / 20% of sales) led the regional performance in the ... as well as solid contributions from Korea, India and ... Middle East / Africa (Q2 2015: +3% ... Turkey and the United Kingdom . ... U.S. HPV sales, on demand across all customer classes. The top seven emerging ...
(Date:7/29/2015)... ... July 29, 2015 , ... G-CON Manufacturing, Inc., the ... their 2nd generation cell therapy POD® design. The 2nd generation portfolio not only ... a new POD® design. , “G-CON first offered our miniPOD CT product ...
Breaking Biology Technology:Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20QIAGEN Reports Results for Second Quarter and First Half of 2015 2QIAGEN Reports Results for Second Quarter and First Half of 2015 3QIAGEN Reports Results for Second Quarter and First Half of 2015 4QIAGEN Reports Results for Second Quarter and First Half of 2015 5QIAGEN Reports Results for Second Quarter and First Half of 2015 6QIAGEN Reports Results for Second Quarter and First Half of 2015 7QIAGEN Reports Results for Second Quarter and First Half of 2015 8QIAGEN Reports Results for Second Quarter and First Half of 2015 9QIAGEN Reports Results for Second Quarter and First Half of 2015 10G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 2G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 3
... (Nasdaq: DNDN ) today announced that management will present ... in New York City, NY on May 25, 2011 at 1:00 ... Palos Verdes, CA on June 7, 2011 at 2:00 p.m. PT ... available for replay from Dendreon,s website, www.dendreon.com .  If you ...
... May 19, 2011 Advances that CSL Behring ... unmet therapeutic needs of patients with hemophilia A and B ... international medical congress on May 22, 2011. CSL Behring is ... and is a subsidiary of CSL Limited (ASX:CSL). ...
... Calif., May 19, 2011 The 2012 federal budget ... Nanotechnology Initiative (NNI), a federal interagency research and development ... of matter at the nanoscale—a measurement of particles between ... in size.  While nanoscale materials are found in nature ...
Cached Biology Technology:Overview of CSL Behring Innovations in Recombinant Technologies Presented at International Conference 2Overview of CSL Behring Innovations in Recombinant Technologies Presented at International Conference 3Environmental Training Center Prepares Companies to Handle Nanotechnology Environmental and Human Safety Impacts 2
(Date:7/27/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), ... announced that Huawei has selected the Synaptics ® ... stylish smartwatch. Huawei chose the state-of-the-art ClearPad capacitive ... and highly responsive human interface qualities such as ... required a classic round watch face and Synaptics ...
(Date:7/21/2015)... Connecticut , July 21, 2015  NXT-ID, ... "Company"), a biometric authentication company focused on the ... Wocket® smart wallet, announces that it has filed ... System and Method. This invention ... not only authorizes an account, but also the ...
(Date:7/9/2015)... , July 9, 2015  Synaptics Inc. (NASDAQ: ... announced today that it will report financial results for ... July 30, 2015 after the close of market. The ... and investors at 2:00 p.m. PT (5:00 p.m. ET), ... To participate on the live call, analysts and ...
Breaking Biology News(10 mins):Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2
... January 8, 2008 Schizophrenia is a developmental disorder ... Available antipsychotic medications treat some of the symptoms ... subset of patients. Unfortunately, it is difficult to ... given individual with schizophrenia. John H. Krystal, M.D., ...
... Technical, Products ... Liability Background, WASHINGTON, Jan. 7 ... McWhorter as a principal who will,provide clients with strategic plans as ... will be ensuring that,the firm,s clients are knowledgeable about the SAFETY ...
... engineers at Purdue University are the first to mathematically ... to electric fields, an advance that could have applications ... The technique of using small droplets created by subjecting ... of applications, from a type of industrial painting called ...
Cached Biology News:Genetic variant predicts antipsychotic response for schizophrenia patients by ethnicity 2Chemist Brings SAFETY Act Expertise to Homeland Security Firm 2'Electrospray' droplet research yields surprising, practical results 2'Electrospray' droplet research yields surprising, practical results 3
b-Catenin (pSer675), phospho-specific...
MAb to Transferrin Dry Ice: No Preservative: NaN3 Availability When Not in Inventory: 14-21 Business Days...
Anti-ADAMTS-4, disintegrin-like domain Immunogen: Synthetic peptide - KLH conjugated Available Date: 38569...
WD-repeat protein 4...
Biology Products: